Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Tamta Makharadze(Batumi State Maritime Academy), Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, К. К. Лактионов(Ministry of Health of the Russian Federation), Gia Nemsadze, Marina Nechaeva(Chelyabinsk Regional Clinical Oncology Center), Irina Rozhkova, Ewa Kalinka‐Warzocha(Polish Mother’s Memorial Hospital Research Institute), Siyu Li(Regeneron (United States)), Yuntong Li(Regeneron (United States)), Manika Kaul(Regeneron (United States)), Ruben G.W. Quek(Regeneron (United States)), Jean‐François Pouliot(Regeneron (United States)), Frank Seebach(Regeneron (United States)), Israel Lowy(Regeneron (United States)), Giuseppe Gullo(Regeneron (United States)), Petra Rietschel(Regeneron (United States))
Cited by 94Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis